BioMarin Pharmaceutical (BMRN) is back in focus after raising its full year 2026 revenue outlook to US$3.83b to US$3.93b and releasing fresh VOXZOGO clinical data in children with achondroplasia.

Despite the raised 2026 revenue guidance and encouraging VOXZOGO data, BioMarin Pharmaceutical’s share price has drifted, with the 90 day share price return down 9.39% and the 3 year total shareholder return down 43.20%, pointing to fading momentum.

If this kind of rerating risk has your attention, it might be a good time to broaden your watchlist and check out 34 healthcare AI stocks

With the share price down over the past 1, 3 and 5 years despite higher 2026 revenue guidance and positive VOXZOGO data, the key question is whether BioMarin looks overlooked or if the market already reflects future growth potential.

Most Popular Narrative: 39.2% Undervalued

At a last close of $54.06 against a narrative fair value of $88.87, the most followed view frames BioMarin as materially discounted, with future earnings power under close scrutiny.

Recent acquisition of Inozyme and ongoing business development initiatives broaden BioMarin's enzyme therapy portfolio and introduce new high-value therapies targeting severe unmet needs, enhancing diversification and durability of revenue streams over the long term.

Curious what kind of revenue mix, margin profile, and earnings multiple would justify that fair value gap? The narrative sets out a detailed playbook, and the exact assumptions may surprise you.

Result: Fair Value of $88.87 (UNDERVALUED)

However, this depends on VOXZOGO avoiding meaningful competitive or pricing pressure, and on pipeline programs clearing regulatory hurdles without costly delays that could unsettle earnings expectations.

Another View: Earnings Multiple Flags a Very Different Story

While the narrative fair value points to BioMarin as undervalued, the P/E ratio of 38.9x tells a tougher story. It sits well above the US Biotechs average of 17.7x and a fair ratio of 23.2x, which suggests meaningful valuation risk if expectations reset.

That kind of gap can close in more than one way. It is worth asking whether the current price mainly reflects future growth hopes, or if the market is still re-rating past execution.

Next Steps

With sentiment clearly split between opportunity and risk, now is the time to review the numbers for yourself and decide where you stand. This includes weighing up 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If this situation has you rethinking your exposure, use the tools available now so you are not relying on a single stock to carry your thesis.

• Spot potential bargains backed by solid fundamentals using the 49 high quality undervalued stocks before others start paying attention.
• Prioritise resilience by scanning for companies that look sturdier on the balance sheet with the solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for opportunities the crowd might be missing through the screener containing 21 high quality undiscovered gems while they still sit off most radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.